Sfakianakis G N, Bourgoignie J J, Jaffe D, Kyriakides G, Perez-Stable E, Duncan R C
J Nucl Med. 1987 Sep;28(9):1383-92.
Renal scintigraphy with [99mTc]diethylenetriaminepentaacetic acid (DTPA) and/or sodium-iodine-131-o-iodohippurate (HIP) was performed before and after an oral dose of captopril (50 mg) in 18 patients with renovascular hypertension (RVH) due to renal artery stenosis (RAS) and 18 controls. In every patient with RVH, captopril induced, enhanced or sustained abnormal findings on HIP scintigraphy depending on the degree of RAS. With DTPA scintigraphy, renal function decreased after captopril in ten kidneys with RVH-related RAS and adequate baseline renal function, but this phenomenon was not evident in 11 kidneys with RVH and poor renal function. Captopril did not influence HIP or DTPA studies of kidneys with patent renal arteries (patients after successful renal angioplasty, patients with essential hypertension, contralateral kidneys of patients with unilateral RVH) or ipsilateral kidneys with mild and subcritical (less than 60%) RAS in patients without hypertension and/or normal renal vein renin activity. When HIP and DTPA scintigraphy were compared in the same patients, HIP demonstrated greater sensitivity and specificity than DTPA, particularly in patients with poor renal function. HIP scintigraphy before and after a single dose of captopril may provide a rapid sensitive and minimally invasive test for screening patients with hypertension.
对18例因肾动脉狭窄(RAS)导致肾血管性高血压(RVH)的患者及18例对照者,在口服卡托普利(50毫克)前后分别进行了用[99mTc]二乙三胺五乙酸(DTPA)和/或碘-131 -邻碘马尿酸钠(HIP)的肾闪烁扫描。在每例RVH患者中,根据RAS的程度,卡托普利可诱发、增强或维持HIP闪烁扫描的异常表现。对于DTPA闪烁扫描,在10例存在与RVH相关的RAS且基线肾功能正常的肾脏中,卡托普利给药后肾功能下降,但在11例RVH且肾功能不佳的肾脏中,这种现象并不明显。卡托普利对肾动脉通畅的肾脏(肾血管成形术成功后的患者、原发性高血压患者、单侧RVH患者的对侧肾脏)或无高血压和/或肾静脉肾素活性正常患者中存在轻度和临界以下(小于60%)RAS的同侧肾脏的HIP或DTPA检查无影响。当在同一患者中比较HIP和DTPA闪烁扫描时,HIP显示出比DTPA更高的敏感性和特异性,尤其是在肾功能不佳的患者中。单次服用卡托普利前后的HIP闪烁扫描可为高血压患者的筛查提供一种快速、灵敏且微创的检测方法。